DOT1L Epigenetically Induces the Expression Level of FoxM1 through H3K79me2 and Affects the Malignant Behaviors of Head and Neck Squamous Cell Carcinoma Cells-Reference-Cited by-同舟云学术

DOT1L Epigenetically Induces the Expression Level of FoxM1 through H3K79me2 and Affects the Malignant Behaviors of Head and Neck Squamous Cell Carcinoma Cells

Published:2022 Issue:2 Volume:31 Page:101-108
ISSN:1341-7649
Container-title:Journal of Hard Tissue Biology
language:en
Short-container-title:J. Hard Tissue Biology.

Author:

Du Huanle¹,Zhang Lin¹

Affiliation:

1. Otolaryngology Head and Neck Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine

Publisher

Society for Hard Tissue Regenerative Biology

Subject

Cell Biology,General Dentistry,Orthopedics and Sports Medicine,Biomaterials,Biochemistry,Medicine (miscellaneous)

Link

https://www.jstage.jst.go.jp/article/jhtb/31/2/31_101/_pdf

Reference35 articles.

1. 1. Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK and Cui Y. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol 7: 52, 2019

2. 2. Majchrzak E, Szybiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, Sowka M, Golusinski P, Malicki J and Golusinski W. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: A review of the literature. Radiol Oncol 48: 1, 2014

3. 3. Arantes LMRB, De Carvalho AC, Melendez ME and Lopes Carvalho A. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev Mol Diagn 18: 85-112, 2018

4. 4. Rathod S, Gupta T, Ghosh-Laskar S, Murthy V, Budrukkar A and Agarwal J. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): Evidence from a prospective randomized study. Oral Oncol 49: 634-642, 2013

5. 5. Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, Yang CZ, Han ZG, Guo W, Chen WT and Zhang P. XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PloS one 7: e31601, 2012